Solid Tumor Oncology

Anatomic Pathology

Morphology

Surgical Pathology Consultation [SPC]

Immunohistochemistry & Special Stains

Refer to A-Z listing for IHC Markers

Cytogenetics

Chromosome Analysis Solid Tumor [CYTO ST]

Molecular Oncology

Next Generation Sequencing (NGS)

BRAF Mutation Analysis [M BRAF]

Colorectal Cancer NGS Panel [M COLON NGS]
BRAF, KRAS, NRAS

EGFR Mutation Analysis [M EGFR]

GIST NGS Panel - *KIT, PDGFRA* [M ST GIST NGS]

IDH1/IDH2 Mutation Analysis [M IDH1/2]

KRAS Mutation Analysis [M KRAS]

KIT Mutation Analysis [M KIT]

Lung Cancer NGS Panel [M LUNG NGS]
BRAF, EGFR, KRAS, NRAS

Melanoma Cancer NGS Panel [M MELAN NGS]
BRAF, KIT, NRAS

Solid Tumor 8 Gene NGS Panel [M 8GENE NGS]
BRAF, EGFR, IDH1, IDH2, KIT, KRAS, NRAS, PDGFRA

Fluorescence in situ Hybridization

ALK 2p23 rearrangement [FP ALK]

BCL6 3q27 rearrangement [FP BCL6]

Burkitt / "Double Hit" Large B-cell Lymphoma Panel [FP BURKITT]
C-MYC, BCL2, BCL6

C-MYC 8q24 rearrangement [FP CMYC]

EGFR amplification 7p11.2 [FP EGFR]

HER2/neu Breast Cancer [FP HER2]

HER2/neu Gastric Cancer [FP HER2 GA]

IGH 14q32 rearrangement [FP IGH]

IGH/BCL1 (*CCND1*) t(11;14) [FP BCL1]

IGH/BCL2 t(14;18) [FP BCL2]

IGH/MALT1 t(14;18) [FP IGH MALT]

IGH/MYC t(8;14) [FP IGH MYC]

MALT1 18q21 rearrangement [FP MALT]

Oligodendroglioma, 1p-, 19q- [FP GLI]

ROS1 6q22.1 rearrangement [FP ROS1]

Hematology Oncology

Anatomic Pathology

Morphology

Bone Marrow Pathology Evaluation [BMPE]

Surgical Pathology Consultation [SPC]

Immunohistochemistry & Special Stains

Refer to A-Z listing for IHC Markers

Cytogenetics

Chromosome Analysis Bone Marrow [CYTO BM]

Chromosome Analysis Lymphoma (Lymph Node) [CYTO LN]

Chromosome Analysis Leukemic Peripheral Blood [CYTO LPB]

Flow Cytometry

Flow Cytometry Leukemia / Myeloma / Lymphoma [FLOW]

Flow Cytometry Technical Only [FLOW TC]

Flow Cytometry and Morphology [FLOW M]

Bronchoalveolar Lavage [FLOW BAL]
CD4:CD8 ratio

Leukocyte Adhesion Deficiency [FLOW LAD]
CD11a, CD11b, CD11c, CD18

Paroxysmal Nocturnal Hemoglobinuria - High Sensitivity [FLOW PNH]
FLAER, CD14, CD24, CD59

Molecular Oncology

Next Generation Sequencing (NGS)

Calreticulin type 1 / type 2 Mutation Analysis [M CALR]

JAK2 Exon 12 Mutation [M JAK2 EX12]

MPL Exon 10 Mutation [M MPL]

MYD88 p.L265P Mutation [M MYD88]

Myeloproliferative Neoplasms Core Mutation Panel [M MPN Core]
JAK2 V617F, JAK2 EXON 12, CALR, MPL

Myeloid Neoplasms Extended Mutation Panel [M MPN Extended]
JAK2 (V617F and Exon 12), CALR (Type 1 and 2), MPL, ASXL1, CBL, CSF3R, ETV6/TEL, EZH2, IDH1, IDH2, KIT, KRAS, NRAS, RUNX1, SETB1, SF3B1, SRSF2, TET2, TP53

AML Mutation Analysis Panel [M AML]
ASXL1, DNMT3A, FLT3, IDH1, IDH2, KIT, NPM1, RUNX1, TET2, TP53, WTI

IgVH Somatic Hypermutation [M IgVH]

B-Cell IGH Gene Rearrangement [M BCELL]

B-Cell IGK Gene Rearrangement [M IGK]

T-Cell Gene Rearrangement [M TCR]

BCR/ABL qRT PCR Major p210 & Minor p190 transcripts [M BCR ABL]

JAK2 V617F Mutation [M JAK2]

Rev MAY2018

Fluorescence in situ Hybridization (FISH)

Hematology Panels

Adult Acute Lymphoblastic Leukemia Panel [F AALL]
t(9;22), t(12;21), *MLL*(KMT2A)

Burkitt "Double Hit" Large B-cell Lymphoma Panel [F BURKITT]
C-MYC, BCL2, BCL6

Chronic Lymphocytic Leukemia Panel [F CLL]
MYB (6q23), *ATM* (11q22.3), +12, *DLEU1* (13q14.3), *TP53* (17p13)

Myelodysplasia Panel [F MDS]
-5/5q-, -7/7q-, +8, 20q-

Myeloproliferative Neoplasms Panel [F MPD]
+8, t(9;22), 13q-, 20q-

Plasma Cell Neoplasm Panel [F MM]
1p-, 1q+, +5, +9, t(11;14), 13q-, +15, 17p-, reflex t(4;14) / t(14;16)

Hematology Probes

AML1(*RUNX1*)/*ETO*(RUNXT1) t(8;21) [F AML ETO]
API2/MALT1 t(11;18) [F API MALT]
ATM/CEP11 deletion 11q22.3 [F ATM]
BCL6 3q27 rearrangement [F BCL6]
BCR/ABL1 t(9;22) [F BCR ABL]
CBFB t(16;16), inv(16) [F CBFB]
CEP 7 -7/7q31 [F CEP7]
C-MYC 8q24 rearrangement [F CMYC]
Deletion 7q22 [D7S796, D7S658]/7q31.2 [D7S486] [F 7q]
Deletion 13q14.3 [F D1314]
Deletion 20q12 [F D20]
EGR1 5q deletion, monosomy 5 [F EGR1]
FIPIL1/PDGFRA 4q12 gene rearrangement [F 4q12]
IGH 14q32 rearrangement [F IGH]
IGH/BCL1 (*CCND1*) t(11;14) [F BCL1]
IGH/BCL2 t(14;18) [F BCL2]
IGH/FGFR3 t(4;14) [F FGFR3]
IGH/MAF t(14;16) [F IGH MAF]
IGH/MALT1 t(14;18) [F IGH MALT]
IGH/MYC t(8;14) [F IGH MYC]
MALT1 18q21 rearrangement [F MALT]
MLL (KMT2A) 11q23 Gene Rearrangement [F MLL]
MYB 6q deletion [F MYB]
PDGFRB Gene Rearrangement [F PDGFRB]
PML/RARA t(15,17) [F PML RARA]
TEL (*ETV6*)/*AML1* (*RUNX1*) t(12;21) [F TEL AML1]
TP53 17p13 deletion [F P53]
Trisomy 5, 9, 15 [F T5T9T15]
Trisomy 8 [F T8]

Women's Health

STD and Infectious Disease

Chlamydia Trachomatis, Qualitative by Aptima COMBO® 2 TMA [CT]
Human Papillomavirus Genotyping [HPV G]
Human Papillomavirus High Risk by Aptima HPV [HPV HR]
Herpes Simplex Virus Type 1 and 2 Qualitative by PCR [HSV]
Neisseria Gonorrhoeae Qualitative by Aptima COMBO® 2 TMA [NG]
Trichomonas Vaginalis by Aptima [TV]

Other

Fluorescence in situ Hybridization (FISH)

Bladder Cancer Panel [F URO]
+3,+7,+17,9p21-

Molar Pregnancy Panel [FP ANEU]
+13,+18,+21, X, Y

Cytogenetics

Chromosome Analysis Peripheral Blood (Constitutional) [CYTO PB]
Chromosome Analysis Products of Conception [CYTO POC]